SF3B1 and myelodysplastic syndrome: Another breakthrough was the introduction of co-transplantation of MSCs with hematopoietic cells from MDS patients into immunocompromised mice which has shown mixed results, but while some studies report stable engraftment of mutations like RUNX1 and SF3B1, others find MSCs provide only temporary support [6–9].